Fintel reports that on July 17, 2025, Cantor Fitzgerald initiated coverage of Scholar Rock Holding (NasdaqGS:SRRK) with a ...

The venture by Richard Yoon and Sam Smith seeks to offer college consulting by students who were in their clients’ shoes not ...

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial ...

Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly. Scholar Rock, a biopharma company ...

Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. Scholar Rock's C-suite now looks ...

Biotech stock Scholar Rock (SRRK -1.28%) was popular among investors on Wednesday after a positive new analyst note on the company made the rounds.

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress Feb. 27, 2025 7:00 AM ET Scholar Rock Holding Corporation (SRRK) ...

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other ...

Wedbush restated their outperform rating on shares of Scholar Rock (NASDAQ:SRRK – Free Report) in a research note published on Wednesday,RTT News reports. They currently have a $47.00 target ...

CAMBRIDGE, Mass., January 08, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA ...

I analyze Scholar Rock's promising Phase 3 results for SMA drug, but warn of financial challenges and recommend a Hold rating. Read more here.